




AMERICAN
ASSOCIATION FOR THE
ADVANCEMENT OF
SCIENCE

SCIENCE

28 NOVEMBER 1997
VOL. 278 • PAGES 1533-1676

\$7.00



New Eagle Eye Lineup

S T R A T A G E N E

Microscope Camera Kit

- Avoids expense of dedicated microscopy system
- Connects microscope to Eagle Eye II system
- Ideal for fluorescence microscopy imaging

Economical Camera Stand

- For white-light imaging or darkroom use
- Perfect camera position without adjusting of
- All imaging and processing capabilities of

Light-Tight Benchtop Cabinet

- Images and analyzes at the bench
- Holds any size transilluminator
- Overhead UV and fluorescent white lights
- Detects chemiluminescence using integration of up to 55 minutes

Stratagene's Eagle Eye® still video imaging system has expanded its field of vision. New innovations in the Eagle Eye lineup now allow this versatile system to be configured for the benchtop, darkroom or light microscopy. The choice is yours.


All three setups let you take advantage of the Eagle Eye II system's advanced image capture and processing capabilities. So whether documenting gels, blots, autoradiographs or FISH analysis, you can display, enhance, archive, retrieve, print and analyze your digital images. Ask about our new Eagle Sight® software analysis features including molecular weight analysis and colony/plaque counting.

For specific information about the best Eagle Eye system for you, please call 1-800-424-5444 or your nearest Stratagene distributor.


Circle No. 27 on Readers' Service Card

United States:
Stratagene Headquarters
800-424-5444
Internet Mail:
techservices@stratagene.com
Australia: 02 9417 7866
Austria: (0222) 3 68 9951
Brazil: 11 5561 1771
Canada: 905 713 1201
Denmark: 8 6101055
France: 1 34 60 2424
Germany: 0130-840911
Hong Kong: 3783839
Israel: 03-5761520
Italy: 258013409
Japan: (Fumakoshi) 3-5684-1622
Korea: 2 5560311
Malaysia: 37031888

The Netherlands: 33 4950094
New Zealand: 9 443 5867
Norway: 22 20 01 87
Portugal: 441-0684
Singapore: 2730898
Spain: 1 729 03 33
Sweden: 8 680 0845
Switzerland: 061-6930540
Thailand: 23080611
United Kingdom: 0800 583370
OTHER COUNTRIES CALL
STRATAGENE U.S.A. (619) 535-5400



Eicosanoid and Cyclic Nucleotide Immunoassays



Looking for an easier method to measure Eicosanoids and Cyclic Nucleotides?

R&D Systems' Eicosanoid and Cyclic Nucleotide Immunoassays are:

- simple
- accurate
- rapid
- sensitive

EICOSANOIDS

FACTOR	CATALOG NO.	RANGE (pg/mL)	SENSITIVITY (pg/mL)	TIME (hrs)
LTB ₄	DE0200	200 – 125,000	30.10	5.00
PGE ₁	DE1200	19.5 – 5000	5.95	2.75
PGE ₂	DE0100	39 – 5000	36.20	2.75
6-keto-PGF _{1α}	DE0800	16 – 50,000	1.40	2.75
PGF _{2α}	DE1100	12.2 – 50,000	4.62	2.75
8-iso-PGF _{2α}	DE0900	24 – 100,000	12.30	2.75
Total 8-iso-PGF _{2α}	DE1000	12.2 – 50,000	11.40	2.75
11β-PGF _{2α}	DE1300	32 – 500,000	4.30	2.75

CYCLIC NUCLEOTIDES

FACTOR	CATALOG NO.	RANGE (pmol/mL)	SENSITIVITY (pmol/mL)	TIME (hrs)
cAMP	DE0400	0.5 – 5000	0.38	2.75
cAMP (low pH)	DE0300	0.5 – 5000	0.74	2.75
cGMP	DE0600	0.8 – 500	0.37	2.75
cGMP (low pH)	DE0500	0.8 – 500	0.58	2.75

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES.

North America
R&D Systems, Inc.
614 McKinley Place NE
Minneapolis, MN 55413, USA
Tel: 612 379-2956
Fax: 612 379-6580
info@randsystems.com

Europe
R&D Systems Europe Ltd.
4-10 The Quadrant, Barton Lane
Abingdon, OX14 3YS, UK
Tel: +44 (0)1235 551100
Fax: +44 (0)1235 533420
info@randsystems.co.uk

Germany
R&D Systems GmbH
Borsigstrasse 7
65205 Wiesbaden, Germany
Tel: +49 (0)6122 90980
Fax: +49 (0)6122 909819
info@randsystems.co.uk

Japan
Funakoshi, Co., Ltd.
9-7, 2-Chome
Hongo, Bunkyo-ku
Tokyo 113, Japan
Tel: +81-3 5684-1622
Fax: +81-3 5684-1633

International Distributors – Argentina: 54-1-942-3654. Australia: 61-2-9521-2177. Austria: 43-1-292-3527.
Chile: 56-2-264-1576. Greece: 031 322 525. Hong Kong: 852-2649-9988. Israel: 972-3-6459649. Italy: 39 2 25 75377.
Korea: 82-2-569-0781. Mexico: 525-612-0085. New Zealand: 64-9-377-3336. Spain: 34 1 535 39 60. Poland: 48 22 720 44 54.
Portugal: 01 352 87 74. South Africa: 021 981 1560. Taiwan: 886-2-368-3600. Venezuela: 58-2-239-7546.

Europe Free Phone – Belgique/België: 0800 10 468. Danmark: 80 01 85 92. France: 0800 90 72 49.
Nederland: 060 225607. Norge: 800 11033. Sverige: 020 79 31 49. Switzerland: 0800 55 2482.

Circle No. 29 on Readers' Service Card

R&D
SYSTEMS



1-800-343-7475

 www.randsystems.com

*get
discovered!*

*with Genome Systems'
Gene Discovery Array*

- *Discover active and inactive genes in a specific RNA sample*
- *Quickly identify new gene targets for future analysis*



New! *Genome Systems now offers its gene expression array
as the newest resource for genetic research.*

We have arrayed **18,394** unique human genes
from the I.M.A.G.E Consortium (Ilnl)¹ cDNA
Libraries on a single membrane!

These filters can be used to study gene
expression, in parallel, for up to 20% of the
genes in the human genome. Probes made
from mRNA or cDNA libraries can be
hybridized for expression profiling.

The Gene Discovery Array can also be used for
gene finding with probes made from large
genomic clones. Find genes in large
genomic regions as part of a positional
cloning program.

Experiments are done with simple ³²P/³³P
labeling and hybridization techniques. Detection
and analysis using phosphorimaging will allow
for easy identification of the genes.


Researchers can purchase filters for their own
high throughput analysis. Two filters are provided
for the assessment of quantifiable differences
between the expression of genes from two
different RNA sources. All clones are linked to
sequence information in dbEST.

Genome Systems can perform custom
screening of the Gene Discovery Array. In just
days we will provide complete data via
confidential web access.

Circle No. 11 on Readers' Service Card

1. "The I.M.A.G.E Consortium: An Integrated Molecular Analysis of Genomes and their Expression", Lennon, G.G., Auffray, C., Polymeropoulos, M., and Soares, M.B. [1995] Genomics.

Genome Systems is an equal opportunity employer.



call for our latest catalogue
800. 430. 0030

GenomeSystemsInc™

4633 World Parkway Circle

St. Louis, Missouri 63134-3115

Voice: 800. 430. 0030 or 314. 427. 3222

FAX: 314. 427. 3324

email: gda@genomesystems.com

World Wide Web:

<http://www.genomesystems.com>

France: Appel gratuit, 0590. 2104

Germany: Rufen sie uns an zum ortstarif,
0130. 81. 9081

UK: Call us free on, 0800. 89. 3733



1565

Africa's preeminent AIDS project



1576

Mantle message from space

NEWS

- Germany's Bleak Future in Space 1554
France Brings Space Goals Down to Earth 1555
- Native Claims Muddy Waters in Fight Over Australian Lake 1556
Science Squeezed Out of Debate 1557
- Libraries Join Forces on Journal Prices 1558
- Women's Health Research: A 5-Year Initiative Slowly Takes Shape 1558
- Japan: Pending Reform Plan Lacks Detail 1559
- Brighter Omens for Giant Reactor? 1559
- Multiple Clocks Keep Time in Fruit Fly Tissues 1560
- Spacecraft Offers Details of Antarctica 1562
- Sex Frees Viruses From Genetic 'Ratchet' 1562
- Viruses Scout Evolution's Path 1563
- New Developmental Clock Discovered 1564

SPECIAL NEWS REPORT

- The Rise and Fall of Projet SIDA 1565

PERSPECTIVES

- Minerals in the Deep Earth: A Message from the Asteroid Belt 1576
D. Stöffler
- Fashioning Flow by Self-Assembly 1577
T. McLeish
- A New Player in Cell Death 1578
T. Hoey

POLICY FORUM

- Variations on a Theme: Cataloging Human DNA Sequence Variation 1580
F. S. Collins, M. S. Guyer, A. Chakravarti

ARTICLE

- Thermohaline Circulation, the Achilles Heel of Our Climate System: Will Man-Made CO₂ Upset the Current Balance? 1582
W. S. Broecker

DEPARTMENTS

- THIS WEEK IN SCIENCE** 1541
- EDITORIAL** 1545
Cryptography in America
I. Lerch and M. Gray
- LETTERS** 1547
Using One's Head: A. Caplan and J. C. Venter • Dopamine's Role: J. A. Gray, A. M. J. Young, M. H. Joseph; M. Sarter and J. P. Bruno • Olfactory "Consciousness"? K. M. Dorries • Sexual Selection in Asian Elephants: R. Tiedemann • Corrections and Clarifications
- SCIENTESCOPE** 1553
- RANDOM SAMPLES** 1569
Florida Corals in Bad Shape • Cell Phones Threaten Radio Telescope • Overstimulated by Early Brain Research? • Sex, Eyes, and Videotape • Anticancer Compound Synthesized • Supergrid
- BOOK REVIEWS** 1574
Judging Science, reviewed by M. D. Green • Vignette • Books Received
- AAAS NEWS & NOTES** 1646
- TECH.SIGHT: PRODUCTS** 1647

AAAS Board of Directors

Jane Lubchenco
Retiring President, Chair
Mildred S. Dresselhaus
President
M. R. C. Greenwood
President-elect

Robert D. Goldman
Alice S. Huang
Sheila Jasanoff
Simon A. Levin
Marcia C. Linn
Michael J. Novacek
Anna C. Roosevelt
Jean E. Taylor

William T. Golden
Treasurer
Richard S. Nicholson
Executive Officer

■ **SCIENCE** (ISSN 0036-8075) is published weekly on Friday, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005. Periodicals Mail postage (publication No. 484460) paid at Washington, DC, and additional mailing offices. Copyright © 1997 by the American Association for the Advancement of Science. The title **SCIENCE** is a registered trademark of the AAAS. Domestic individual membership and subscription (51 issues): \$105 (\$58 allocated to subscription). Domestic institutional subscription (51 issues): \$260. Foreign postage extra: Mexico, Caribbean (surface mail) \$55; other countries (air assist delivery) \$90. First class, airmail, student, and emeritus rates on request. Canadian rates with GST available upon request, GST #1254 88122. IPM #1069624. Printed in the U.S.A.

COVER

Chemosensory cells and bristles along the edge of the *Drosophila* wing are marked by a pseudocolored green fluorescent protein signal, driven from the promoter of the circadian clock gene *period*. These cells support independent photoreceptive clocks; multiple tissues

(including the wing) throughout the animal display circadian rhythms in culture. See page 1632 and the related News story on page 1560. [Image: Jeffrey Plautz, Steve Kay, Cynthia Faber Smith]



RESEARCH ARTICLE

Late Pliocene Faunal Turnover in the Turkana Basin, Kenya and Ethiopia 1589

A. K. Behrensmeyer, N. E. Todd, R. Potts, G. E. McBrinn

REPORTS

Platinum-Group Element Abundance Patterns in Different Mantle Environments 1595

M. Rehkämper, A. N. Halliday, D. Barfod, J. G. Fitton, J. B. Dawson

Transitions Between Blocked and Zonal Flows in a Rotating Annulus with Topography 1598

E. R. Weeks, Y. Tian, J. S. Urbach, K. Ide, H. L. Swinney, M. Ghil

Reversible Polymers Formed from Self-Complementary Monomers Using Quadruple Hydrogen Bonding 1601

R. P. Sijbesma, F. H. Beijer, L. Brunsveld, B. J. B. Folmer, J. H. K. Ky Hirschberg, R. F. M. Lange, J. K. L. Lowe, E. W. Meijer

Two-Dimensional Melting of an Anisotropic Crystal Observed at the Molecular Level 1604

H. D. Sikes and D. K. Schwartz

Enhanced Intergrain Tunneling Magnetoresistance in Half-Metallic CrO₂ Films 1607

H. Y. Hwang and S.-W. Cheong

Imaging of Intermittency in Ripple-Wave Turbulence 1609

W. B. Wright, R. Budakian, D. J. Pine, S. J. Putterman

IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling 1612

M. Muzio, J. Ni, P. Feng, V. M. Dixit

Modulating Irrelevant Motion Perception by Varying Attentional Load in an Unrelated Task 1616

G. Rees, C. D. Frith, N. Lavie

Spatial Pattern Formation in an Insect Host-Parasitoid System 1619

J. L. Maron and S. Harrison

The Spatial Dimension in Population Fluctuations 1621

E. Ranta, V. Kaitala, P. Lundberg

Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors 1623

J. Cui, T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, M. Taniguchi

CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides 1626

T. Kawano, J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki, M. Taniguchi

Defective TNF- α -Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases 1630

A. Kumar, M. Commane, T. W. Flickinger, C. M. Horvath, G. R. Stark

Independent Photoreceptive Circadian Clocks Throughout *Drosophila* 1632

J. D. Plautz, M. Kaneko, J. C. Hall, S. A. Kay

The Filamentous Phage pIV Multimer Visualized by Scanning Transmission Electron Microscopy 1635

N. A. Linderroth, M. N. Simon, M. Russel

Nuclear Accumulation of NFAT4 Opposed by the JNK Signal Transduction Pathway 1638

C.-W. Chow, M. Rincón, J. Cavanagh, M. Dickens, R. J. Davis

Independent and Additive Effects of Central POMC and Leptin Pathways on Murine Obesity 1641

B. A. Boston, K. M. Blaydon, J. Varnerin, R. D. Cone



1638

Transcriptional control by exclusion

■ Indicates accompanying feature

Change of address: allow 4 weeks, giving old and new addresses and 8-digit account number. **Postmaster:** Send change of address to *Science*, P.O. Box 1811, Danbury, CT 06813-1811. **Single copy sales:** \$7.00 per issue prepaid includes surface postage; bulk rates on request. **Authorization to photocopy** material for internal or personal use under circumstances not falling within the fair use provisions of the Copyright Act is granted by AAAS to libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that \$4.00 per article is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923. The identification code for *Science* is 0036-8075/93 \$4.00. *Science* is indexed in the *Reader's Guide to Periodical Literature* and in several specialized indexes.

On the Web

Subscribe now to
**Science's daily
news service**

www.sciencenow.org

ScienceNOW




The Peltier-effect Thermal Cycler That Began A Technological Trend: The MJ RESEARCH PTC-100



Left to right: A PTC-100-96AgV with a speedy silver-gold block that can ramp at up to 2.5°C/sec, a PTC-100HB with improved Hot Bonnet heated lid that applies heat and pressure to the tops of tubes or plates for oil-free reactions, and a PTC-100-16MS that holds 16 slides & 24x0.2ml tubes for *in situ*.

How Peltier-effect Heat Pumps Actually Work

The Peltier effect is a solid-state physical phenomenon that was first described by Jean Peltier in the *Annales de chimie* in 1834. Peltier observed that when current passes through a bimetallic junction, one side gets hot and the other gets cold. In the 20th century, this "effect" has been combined with semiconductor technology to construct small, bi-directional heat pumps that are electronic in nature. These pumps are extremely precise and reliable, and they are the basis of MJ cyclers.



RIGHT WAY TO USE PELTIER

It is now widely accepted that Peltier heat pumps are the best technology for thermal cyclers—but exactly how these pumps are applied is critical. A design was pioneered with the PTC-100 where the pumps are mounted between a low-mass sample block and a large, efficient heat sink. Permanent mounting allows fast, efficient heat flow between the pumps and the block. The heat sink can store heat to be later pumped back into the sample block, or it can disperse the heat to outside air—this depends upon the action of a computer-controlled fan.

The Cycler That Went To War in the Persian Gulf and Battled Plague in India

When adversity flared in the Persian Gulf six years ago, the tools of molecular biology were brought to the front. Biological weapons were threatening; means to detect their use were needed. PTC-100s were there—and they did their duty.

In 1994, unsettling reports were circulating that plague had erupted in Surat, India. Indian authorities were addressing the problem as best they could, but the skills to detect *Y. pestis* had atrophied over time. Working with the WHO, MJ RESEARCH donated several PTC-100s, allowing Indian scientists to use molecular methods to battle the disease. In the final analysis, *only* these molecular tests* proved that the plague pathogen was ever present (see *Nature Med* 1:1237-9).

* PCR is covered by patents owned by Hoffmann-La Roche, Inc. & F. Hoffmann-La Roche Ltd. Users should obtain license to perform the reaction.



MJ Engineer Paul Titcomb in 1990, with a PTC-100 that was camouflaged by the U.S. Marine Corps for field use in *Operation Desert Storm*.

A MUCH-COPIED DESIGN

First Introduced in 1988 and Improved Over Time—It Still Outperforms Most Cyclers

WATERTOWN, Mass. — In 1986 and 1987, much "buzz" was circulating in the biology community about a new method for identifying and amplifying sequences of DNA that was being developed by the Cetus Corporation. A tantalizing paper describing an early form of PCR* had appeared in *Science* in late '85, but a critical refinement—the use of thermostable polymerase enzyme—was not described officially until '88. At that time, the need for significant numbers of instruments to thermally cycle tiny aliquots of biological reagent first became apparent.

The partner of the Cetus Corporation, The Perkin-Elmer Corporation, concentrated on the development of a thermal cycler based upon mechanical vapor compression technology. MJ RESEARCH, INC.—then a year-old start-up company—recognized the opportunity and began development of instrument based upon the more promising Peltier-effect heat pump. Several other companies in the U.S. and England also began development of thermal cyclers—mostly based upon resistive heating and passive air or water cooling (though one other US firm also developed a variant of the Peltier cycler).

In late '88, MJ RESEARCH introduced the world's first Peltier thermal cycler—the PTC-100. Since that time, the instrument's design has been modified, crafted, tweaked—and perfected. To this day, the PTC-100 outperforms most competing cyclers in uniformity, speed, accuracy, and capacity—even though at least twenty other manufacturers have since entered the market. MJ has introduced newer designs—the Mini-Cycler, DNA Engine, and Tetrad—yet the PTC-100 remains a respected workhorse of science.

But perhaps the greatest compliment to this pioneering design is the ubiquitous imitation. Though it was scorned at first by some, the PTC-100's configuration is now mimicked by virtually every manufacturer in every new introduction.

E-MAIL: SALES@MJR.COM • WEB: HTTP://WWW.MJR.COM



MJ RESEARCH, INC.

Manufacturer of Peltier-effect Thermal Cyclers

149 Grove St. • Watertown, MA 02172 USA

(888) PELTIER • Fax (617) 923-8080

Distributors Worldwide—Fax, E-mail or Web for List

THIS WEEK IN SCIENCE

edited by PHIL SZUROMI

Reversible polymers

Polymers that form through hydrogen bonding could have interesting properties, such as reversibility of the polymerization through heating or concentration change. However, insufficient strength and directionality of the bonding between the monomer units have hampered progress. Sijbesma *et al.* (p. 1601; see the Perspective by McLeish, p. 1577) found that highly directional polymerization resulted for monomer units bearing a self-complementary array of four hydrogen bonds. Viscosity, chain length, and composition can be tuned by changing conditions.

Current events

Ocean currents are now dominated by thermohaline circulation, the sinking of dense, cool, salty water at high latitudes. Today, approximately equal amounts of deep water are formed in the Arctic and Antarctic. Changes in this pattern are thought to have affected climate greatly in the recent past. Broecker (p. 1582) reviews our present understanding of this circulation pattern and its evolution through time. A critical question is whether increases in greenhouse gases in the atmosphere might disturb this balance and flow pattern.

Melting in 2D

The physics of phase transitions, such as melting, in two-dimensional (2D) systems can differ from that in bulk; theory suggests that a hexagonal crystal, a typical packing, will show an intermediate hexatic phase before melting, but this phase has been difficult to observe. One problem is that defects will distort the packing to orthorhombic, in which case theory predicts that a smectic phase will precede the hexatic phase. Sikes and Schwartz (p. 1604), using high-temperature atomic force microscopy, present evi-

Climate and human evolution

It has recently been suggested that a change to a drier climate in Africa about 2.5 million years ago spurred early human evolution and led to a turnover in mammalian fauna. Behrensmeyer *et al.* (p. 1589) analyzed a large collection of mammalian fossils dating from 3 to 1.8 million years ago from the Turkana Basin in Kenya and Ethiopia. Although the data show that perhaps up to 78 percent of the mammalian fauna turned over during this time, the major change in fauna was not at 2.5 million years ago, but occurred continually afterward.


dence for such a smectic phase in supported Langmuir-Blodgett films of fatty acids.

Stormy weather

Several times a year, large stable weather patterns form and persist for weeks to up to a month or so. Weeks *et al.* (p. 1598) performed an experiment with a rotating annulus to show that this pattern, and the transition to more normal eastward atmospheric flow, reflects interactions of the rotating atmosphere with topography.

Types of attention

Two opposing views of neural implementations of attention are a top-down (or roving spotlight) mechanism or a bottom-up (or competitive inputs) mechanism. Both views are supported by studies of neurological patients, primate experiments, and functional imaging of normal humans. Rees *et al.* (p. 1616) describe a com-



bined functional imaging and psychophysical study of how the degree of visual perception is influenced by the difficulty of simultaneously performing a word-based task. Irrelevant visual stimuli were not perceived only when the task commands large processing resources.

Experiments in space

The spatial aspect of population ecology can be more readily modeled than it can be tested and studied in the field. Two reports help redress the balance. Maron and Harrison (p. 1619) demonstrate experimentally how a host-parasitoid interaction can result in the patchy distribution of a population within a continuous habitat, a result predicted theoretically. Ranta *et al.* (p. 1621) used a 68-year record of the population size of Canadian lynx from eight provinces of Canada to investigate the dynamics of populations in time and space. Notable, but unstable, synchronicities occur, particularly among neighboring populations. These dynamics can be captured by a straightforward model of population dynamics, which suggests that there may be a simple explanation for the phenomenon.

Clocks all over

Most animals are thought to contain central circadian clocks in the brain—mammals in the suprachiasmatic nucleus, and birds and fish in the pineal. Plautz *et al.* (p. 1632; see the cover and the news story by Pennisi, p. 1560) have visualized the expression of the key clock component PER by engineering the protein luciferase together with PER to form a fusion protein. This construct revealed that the fly *Drosophila* contains multiple independent oscillators in peripheral tissues, notably in the chemosensory cells of the wing margin. Each independent clock

can be reset directly by light, likely through as yet undefined photoreceptors.

NKT cells and tumors

An unusual subset of T cells, natural killer T (NKT) cells, all have the same T cell receptor and all bear some NK cell markers; two reports show that they play a role in fighting tumors. Cui *et al.* (p. 1623) now show that these cells seem to be indispensable for the control of syngenic tumors mediated by interleukin-12. The mechanism involves the production of interferon γ by these cells. Kawano *et al.* (p. 1626) found that NKT cells recognize a galactosylceramide lipid found in marine sponges in the context of CD1d; an analog of this lipid may be the natural ligand for antigen recognition. Addition of galactosylceramide in a model of tumor metastasis activated these cells and inhibited development of tumor metastases. Activation of the NKT cells is similar to T cells, but their effector function is more like NK cells.

Ice role for STATs

STATs (signal transducers and activators of transcription) are important mediators of regulated transcription induced by exposure of cells to various cytokines and growth factors. Kumar *et al.* (p. 1630; see the Perspective by Hoey, p. 1541) describe a different role for these transcription factors—constitutive activation of transcription of Ice-family proteases. These proteases function in apoptosis (programmed cell death), and cells that lack STAT1 failed to undergo apoptosis in response to tumor necrosis factor- α . The constitutive transcription of the protease genes is distinct from the regulated transcriptional activation mediated by STAT1 in that dimerization is apparently not required for the former.

DOCTORS HAVE TO BALANCE A MULTITUDE OF VARIABLES IN TREATMENTS. WE MAY BE ABLE TO BRING SOME CERTITUDE TO THE PROCESS.

Every small advance adds yet another tool to medicine. And yet another factor the physician has to store away in his brain, to weigh against hundreds of others in virtually every treatment.

Now add to that the inexorable pressure from healthcare providers to contain costs and increase efficiency.


This is the backdrop for a dramatic new medical technology that may let physicians destroy diseased or target cells with high selectivity, minimal invasiveness, and minimal effect on healthy cells.

PhotoPoint,[™] being developed by

Miravant, utilizes highly-purified synthetic drugs which are activated by a special non-thermal light. Applications as diverse as cancer and eye disease are being examined, most of them likely to be handled on an outpatient basis.

Certain of these drugs appear to naturally collect in rapidly reproducing cells, and by exposing them to a different wavelength of light it may also be possible to make the diseased cells fluoresce, thus creating a completely new diagnostic tool.

In short, this may be one advance which ultimately simplifies the doctor's treatment selection.



PhotoPoint has potential to selectively target a range of abnormal tissues in the body, such as diseases like cancer or retinal abnormalities.



In clinical studies, the PhotoPoint drug is injected and is subsequently retained by target cells. It remains inactive until exposed to a specific wavelength of non-thermal red light.



Light is directed at the target area. A small diode-based system generates the light, and special devices deliver it within the body or on its surface.



Targeted cells are destroyed by an interaction between the drug and the light, with minimal known side effects. PhotoPoint, now in clinical trials, is being developed as an outpatient procedure.

Learn more about PhotoPoint™ and Miravant (Nasdaq: MRVT) at www.miravant.com, or call toll-free at 888-685-6788. The company's products require U.S. Food and Drug Administration approval before marketing.



Circle No. 17 on Readers' Service Card

MEMBERSHIP/CIRCULATION

Deputy Director: Marlene Zendell
Member Services: Michael Lung, *Manager*; Mary Curry, *Supervisor*; Pat Butler, Laurie Baker, Jonathan Keeler, Sherie Jones, Jantell Smith, *Representatives*
Marketing: Dee Valencia, *Manager*; Hilary Baar, *Assistant Manager*; Lauri Sirois, *Coordinator*; Jane Pennington, *Europe Manager*; Ben Holland, *Representative*
Research: Renuka Chander, *Manager*
Business and Finance: Robert Smariga, *Manager*; Susan Maxim, *Assistant*
Computer Specialist: Charles Munson

FINANCE AND ADVERTISING

Business and Finance: Deborah Rivera-Wienhold, *Business Manager*; Randy Yi, *Senior Analyst*; Connie Dang, *Financial Analyst*
Permissions: Lincoln Richman, *Administrator*; Emilie David, *Assistant*
Marketing: John Meyers, *Manager*; Allison Pritchard, *Associate*
Electronic Media: David Gillikin, *Manager*; Wendy Green, *Computer Specialist*; Mark Croatti, Crystal Young, *Production Associates*
Assistant to Associate Publisher: Nancy Hicks

SALES

Product Advertising: Susan A. Meredith, *Advertising Sales Manager*; 503-697-5624, FAX 503-697-5619 • **East Coast/E. Canada:** Richard Teeling; 201-904-9774, FAX 201-904-9701 • **Midwest/Southeast:** Elizabeth Mosko; 773-665-1150, FAX 773-665-2129 • **West Coast/W. Canada:** Neil Boylan; 415-673-9265, FAX 415-673-9267 • **UK/Scandinavia/France/Italy/Belgium/Netherlands:** Andrew Davies; (44) 1-457-871-073, FAX (44) 1-457-877-344 • **Germany/Switzerland/Austria:** Tracey Peers; (44) 1-260-297-530, FAX (44) 1-260-271-022 • **Japan:** Maschy Yoshikawa; (81) 3-3235-5961, FAX (81) 3-3235-5852 • Carol Maddox, *Traffic Manager*; Sheila Myers, *Sales Associate*; Emilie David, *Assistant*

Recruitment Advertising: Terri Seiter Azie, *Sales and Production Operations Manager* • **U.S. Sales:** Gabrielle Boguslawski, *Sales Manager*; 718-491-1607, FAX 202-289-6742; Daryl Anderson, *Sales Supervisor*; Beth Dwyer, Bren Peters-Minnis, *Sales Representatives*; Eric Banks, Troy Benitez, *Sales Associates*; Angela Pantor, *Assistant* • Ellen McGuire, Jennifer Rankin, *Production Associate* • **U.K./Europe:** Debbie Cummings, *Sales Manager*; Sabine Lenud, *Sales Executive*; Michaela Heigl, *Assistant*; (44) 1-223-302-067, FAX (44) 1-223-576-208 • **Australia/New Zealand:** Keith Sandell; (21) 02-922-2977, FAX (61) 02-922-1100 • **Japan:** Maschy Yoshikawa; (81) 3-3235-5961, FAX (81) 3-3235-5852

SCIENCE EDITORIAL BOARD

Charles J. Arntzen
David Baltimore
J. Michael Bishop
William F. Brinkman
E. Margaret Burbidge
Pierre-Gilles de Gennes
Joseph L. Goldstein
Mary L. Good
Harry B. Gray
John J. Hopfield

F. Clark Howell
Paul A. Marks
Yasutomi Nishizuka
Helen M. Ranney
Bengt Samuelsson
Robert M. Solow
Edward C. Stone
James D. Watson
Richard N. Zare

■ Published by the American Association for the Advancement of Science (AAAS), *Science* serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in *Science*—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

■ The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

INFORMATION RESOURCES

SUBSCRIPTION SERVICES

For change of address, missing issues, new orders and renewals, and payment questions, please contact AAAS at Danbury, CT: 800-731-4939 or Washington, DC: 202-326-6417, FAX 202-842-1065. Mailing addresses: AAAS, P.O. Box 1811, Danbury, CT 06813 or AAAS Member Services, 1200 New York Avenue, NW, Washington, DC 20005 • **Other AAAS Programs:** 202-326-6400

MEMBER BENEFIT CONTACTS

Credit Card: MBNA 1-800-847-7378; Car Rentals: Hertz 1-800-654-2200 CDP#343457, Dollar 1-800-800-4000 #AA1115; AAAS Travels: Betchart Expeditions 1-800-252-4910; Life Insurance: Seabury & Smith 1-800-424-9883; Other Benefits: AAAS Member Services 1-202-326-6417.

REPRINTS & PERMISSION

Reprints: Ordering/Billing/Status, 800-407-9190; Corrections, 202-326-6501 • **Permissions:** 202-326-7074, FAX 202-682-0816

INTERNET ADDRESSES

science_editors@aaas.org (for general editorial queries); science_news@aaas.org (for news queries); science_letters@aaas.org (for letters to the editor); science_reviews@aaas.org (for returning manuscript reviews); science_bookrevs@aaas.org (for book review queries); science@science-int.co.uk (for the Europe Office); membership@aaas.org (for member services); science_classifieds@aaas.org (for submitting

classified advertisements); science_advertising@aaas.org (for product advertising)

INFORMATION FOR CONTRIBUTORS

See pages 98–99 of the 3 January 1997 issue or access www.sciencemag.org/misc/con-info.shtml.

EDITORIAL & NEWS CONTACTS

North America

Address: 1200 New York Avenue, NW, Washington, DC 20005
Editorial: 202-326-6501, FAX 202-289-7562
News: 202-326-6500, FAX 202-371-9227 • **Bureaus:**
Berkeley, CA: 510-841-1154, FAX 510-841-6339, **San Diego, CA:** 619-942-3252, FAX 619-942-4979, **Chicago, IL:** 312-360-1227, FAX 312-360-0537, **Boston, MA:** 617-566-7137, FAX 617-734-8088

Europe

Headquarters: 14 George IV Street, Cambridge, UK CB2 1HH; (44) 1223-302067, FAX (44) 1223-302068
Paris Correspondent: (33) 1-49-29-09-01, FAX (33) 1-49-29-09-00

Asia

News Bureau: Dennis Normile, (81) 3-3335-9925, FAX (81) 3-3335-4898; dnormile@twics.com
• **Japan Office:** Carl Kay, Esaka 1-chome 16-10-305, Suita-shi, Osaka-fu 564 Japan; (81) 6-387-5483, FAX (81) 6-337-6809; science@japanese.co.jp
• **China Office:** Hao Xin, (86)10-6255-9478; science@public3.bta.net.cn

BOARD OF REVIEWING EDITORS

Frederick W. Alt
Children's Hospital, Boston
Don L. Anderson
California Institute of Technology
Michael Ashburner
Univ. of Cambridge
Frank S. Bates
Univ. of Minnesota, Minneapolis
Stephen J. Benkovic
Pennsylvania State Univ.
Alan Bernstein
Mount Sinai Hospital, Toronto
Michael J. Bevan
Univ. of Washington, Seattle
Seth Blair
Univ. of Wisconsin, Madison
David E. Bloom
Harvard Institute for International Development
Piet Borst
The Netherlands Cancer Institute
Henry R. Bourne
Univ. of California, San Francisco
James J. Bull
Univ. of Texas at Austin
Kathryn Calame
Columbia Univ. College of Physicians & Surgeons
Dennis W. Choi
Washington Univ. School of Medicine, St. Louis
David Clapham
Children's Hospital, Boston
Adrienne E. Clarke
Univ. of Melbourne, Parkville
F. Fleming Crim
Univ. of Wisconsin, Madison
Paul J. Crutzen
Max-Planck-Institut für Chemie
James E. Dahlberg
Univ. of Wisconsin Medical School, Madison
Robert Desimone
National Institute of Mental Health, NIH
Paul T. Englund
Johns Hopkins Univ. School of Medicine
G. Ertl
Max-Planck-Gesellschaft

Richard G. Fairbanks
Lamont-Doherty Earth Observatory
Robert E. Fay
U.S. Bureau of the Census
Douglas T. Fearon
Univ. of Cambridge
Harry A. Fozzard
The Univ. of Chicago
Roger I. M. Glass
Centers for Disease Control
Peter N. Goodfellow
SmithKline Beecham, UK
Peter Gruss
Max Planck Institute of Biophysical Chemistry
Philip C. Hanawalt
Stanford Univ.
Paul Harvey
Univ. of Oxford
M. P. Hassell
Imperial College at Silwood Park
Nobutaka Hirokawa
Univ. of Tokyo
Tomas Hökfelt
Karolinska Institutet
Tasuku Honjo
Kyoto Univ.
Susan D. Iversen
Univ. of Oxford
Eric F. Johnson
The Scripps Research Institute
Hans Kende
Michigan State Univ.
Elliott Kieff
Harvard Univ.
Jeffrey T. Kiehl
National Center for Atmospheric Research, Boulder
Judith Kimble
Univ. of Wisconsin, Madison
Stephen M. Kosslyn
Harvard Univ.
Michael LaBarbera
The Univ. of Chicago
Antonio Lanzavecchia
Basel Institute for Immunology
Nicole Le Douarin
Institut d'Embryologie Cellulaire et Moléculaire du CNRS
Norman L. Letvin
Beth Israel Hospital, Boston

Harvey F. Lodish
Whitehead Institute for Biomedical Research
Richard Losick
Harvard Univ.
Ruth Lynden-Bell
Queen's Univ., Belfast
Seth Marder
California Institute of Technology
Diane Mathis
Institut de Chimie Biologique, Strasbourg
Susan K. McConnell
Stanford Univ.
Anthony R. Means
Duke Univ. Medical Center
Stanley Meisel
Univ. of California, Davis
Douglas A. Melton
Harvard Univ.
Shigetada Nakanishi
Kyoto Univ.
Kim Nasmyth
Research Institute of Molecular Pathology, Vienna
Roger A. Nicoll
Univ. of California, San Francisco
Staffan Normark
Swedish Institute for Infectious Disease Control
Kiyotaka Okada
Kyoto Univ.
Bert W. O'Malley
Baylor College of Medicine
Roy R. Parker
Univ. of Arizona, Tucson
Stuart L. Pimm
The Univ. of Tennessee, Knoxville
Yeshayau Pocker
Univ. of Washington, Seattle
Ralph S. Quatrano
Univ. of North Carolina, Chapel Hill
Martin Raff
Univ. College London
Douglas C. Rees
California Institute of Technology
T. M. Rice
ETH-Hönggerberg, Zürich
David C. Rubie
Universität Bayreuth
Erkki Ruoslahti
The Burnham Institute, CA

Gottfried Schatz
Biozentrum, Basel
Jozef Schell
Max-Planck-Institut für Züchtungsforschung
Ronald H. Schwartz
National Institute of Allergy and Infectious Diseases, NIH
Terrence J. Sejnowski
Salk Institute
Christopher R. Somerville
Carnegie Institute of Washington
Michael P. Stryker
Univ. of California, San Francisco
Cliff Tabin
Harvard Medical School
John Jen Tai
Academia Sinica, Taiwan
Tomoyuki Takahashi
Univ. of Tokyo
Masatoshi Takeichi
Kyoto Univ.
Keiji Tanaka
RIKEN Institute
David Tilman
Univ. of Minnesota, St. Paul
Robert T. N. Tjian
Univ. of California, Berkeley
Yoshinori Tokura
Univ. of Tokyo
Derek van der Kooy
Univ. of Toronto
Geerat J. Vermeij
Univ. of California, Davis
Bert Vogelstein
Johns Hopkins Oncology Center
Gerhard Wegner
Max-Planck-Institut für Polymerforschung
Arthur Weiss
Univ. of California, San Francisco
Robin A. Weiss
The Institute of Cancer Research, London
Zena Werb
Univ. of California, San Francisco
George M. Whitesides
Harvard Univ.
Martin Zatz
National Institute of Mental Health, NIH



Jump into the World of Convenient and Reliable Protease Inhibition.

Tired of time-consuming searches for the right protease inhibitor? Tired of weighing and dissolving inhibitors? Then try Boehringer Mannheim's Complete™ Protease Inhibitor Cocktail Tablets—a giant step forward in convenient protease inhibition!

Simplify protease inhibition with new Complete Tablets

To inhibit all possible serine, cysteine, and metallo-proteases, simply dissolve one Complete Protease Inhibitor Cocktail Tablet in 50 ml or 10 ml water or aqueous buffer (*e.g.*, cell-lysis buffer). Simplify protein extractions on eukaryotic cell lines, animal tissues, plants, yeast, or bacteria by eliminating the need to weigh inhibitor after inhibitor. With these convenient tablets, you can:

- deliver the same inhibitor dosage every time for greater reliability
- use a product that is non-toxic, readily soluble, and stable in solution for consistent results
- select EDTA-free tablets that will not affect the stability or function of metal-dependent proteins.


Complete Tablets	Vol. per tablet
1697 498 (20 tablets)	50 ml
1836 145 (3 x 20 tablets)	
1836 153 (25 Mini tablets)	10 ml
Complete Tablets, EDTA-free	
1873 580 (20 tablets)	50 ml
1836 170 (25 Mini tablets)	10 ml

Avoid inhibitor binding while inhibiting serine proteases with Pefabloc® SC PLUS

Recent findings indicate that the serine protease inhibitors Pefabloc SC, PMSF, and APMSF bind covalently to proteins under certain conditions. Now you can avoid this problem with Boehringer Mannheim's new Pefabloc SC PLUS (Cat. Nos. 1873 601, 1873 628). This convenient set combines Pefabloc SC with a Pefabloc SC Protector to prevent this binding—without diminishing the inhibitory effect of Pefabloc SC!

Order from our complete protease inhibitor line today!

Or, to learn more about these and our other unique products for protease inhibition, request our revised *Complete Guide for Protease Inhibition* from your Boehringer Mannheim representative.



**BOEHRINGER
MANNHEIM**



Internet <http://biochem.boehringer-mannheim.com>

Complete™ is a trademark of Boehringer Mannheim. Pefabloc® is a registered trademark of Pentapharm AG.

Australia (02) 9899 7999; Austria (0222) 277 87; Belgium (02) 247 4930; Brazil 55 11 66 3565; Canada (514) 686 7050; (800) 361 2070; Chile 00 56 (2) 22 33 737; China 86 21 6416 4320; Czech Republic (0324) 45 54, 58 71-2; Denmark 49 13 82 32; Egypt +20 2 3358815/19; Finland (00) 428 2342; France 04 76 76 30 86; Germany (0621) 759 8545; Greece (01) 67 40 238; Hong Kong (852) 2485 7596; India (22) 837 0794; Indonesia 62 (21) 520 2820; Israel 972-3-6 49 31 11; Italy 02 270 96209; Japan 03 3432 3155; Malaysia 60 (03) 755 5039; Mexico (5) 227 8967, -61; Netherlands (036) 539 4911; New Zealand (09) 276 4157; Norway 22 07 65 00; Poland (22) 36 06 77-87; Portugal (01) 417 17 17; Republic of Ireland 1 800 409041; Russia (49) 621 758 8636; Singapore/Philippines 65 272 7500; South Africa (011) 886 2400; South Eastern Europe +43 (1) 277 87; South Korea 02 569 6902; Spain (93) 201 4411; Sweden (08) 404 88 00; Switzerland 0 41/7 99 6161; Taiwan (02) 736 7125; Thailand 66 (2) 274 0708-13; Turkey 1 349 81 76-79; United Kingdom (0800) 521 578; USA (800) 428 5433.


© 1997 Boehringer Mannheim. All Rights Reserved.

Circle No. 18 on Readers' Service Card


Are your cells set to self-destruct?



ApoAlert™ Apoptosis Products



ApoAlert CPP32 Protease assay detects CPP32 activity soon after induction of apoptosis.



ApoAlert Annexin V assay detects early-stage apoptosis by flow cytometry or fluorescence microscopy.

The **ApoAlert CPP32 Fluorescent and Colorimetric Protease Assay Kits** (#K2026-1, -2, #K2027-1, -2) provide convenient means of detecting CPP32 activity. CPP32 is an ICE-family protease implicated in initiating apoptosis in a variety of systems.

The **ApoAlert Annexin V Apoptosis Kit** (#K2025-1, -2) quickly and easily detects an early apoptosis indicator—the translocation of phosphatidylserine to the outer leaflet of the plasma membrane.

CLONTECH also offers the **ApoAlert DNA Fragmentation Assay** and a variety of apoptosis-inducing reagents, inhibitors, and antibodies. Call **800-662-2566 (CLON)** or contact your local distributor.

In Germany please contact CLONTECH GmbH • Tel: 06221 34170 Fax: 06221 303511

In the U.K. please contact CLONTECH U.K. Ltd. • Tel: 01256 476500 Fax: 01256 476499 (effective 1/1/98)

Australia: 61 2 9417 7866 ■ Austria and Eastern Europe: 43 1 889 1819 ■ Belgium/Luxembourg: 0 800 1 9815
 ■ Canada: Now call CLONTECH direct • 800 662 2566 ■ China: BEIJING YUANGPING BIOTECH • 86 10 68187551; GENE CO. LTD. • 86 21 64748700; HW SCIENCE & TECHNOLOGY DEVELOPMENT CO., LTD. • 86 22 26647265; SINO-AMERICAN BIOTECH CO. • 86 37 94322501; WATSON BIOMEDICALS, INC. • 86 21 65572386
 ■ Czech Republic: 42 19 65214 ■ Egypt: 202 349 8311 ■ France: 33134 602424 ■ Germany: CLONTECH GmbH • 49 6221 34170 ■ Greece: 30 1 483 1190 ■ Hong Kong: 852 2646 6101 ■ India: 091 11 54 21714 ■ Israel: 972 4 9960595 ■ Italy: 39 2 6127621 ■ Japan: 81 6 348 3786 ■ Korea: 82 2 556 0311 ■ Malaysia: 603 777 2608 ■ Mexico: 525 519 3463 ■ The Netherlands: 31 33 495 00 94 ■ Scandinavia: 46 8 749 5940 ■ Singapore: 65 775 7284 ■ Spain/Portugal: 34 1 630 0379 ■ Switzerland: 41 61 272 3924 ■ Taiwan: 886 2 7202215 ■ Thailand: 662 530 3805 ■ Turkey: 90 216 385 8321 ■ United Kingdom: CLONTECH U.K. Ltd. (effective 1/1/98) • 01256 476500 rev. 10/97

CLONTECH

N O W Y O U C A N.

1020 East Meadow Circle, Palo Alto, California 94303 USA

Tel: 800-662-2566 (CLON) 650-424-8222 • Fax: 800-424-1350 650-424-1064


E-mail: tech@clontech.com orders@clontech.com • Internet: http://www.clontech.com

© 1997, CLONTECH Laboratories, Inc.


(AD72394)

Circle No. 16 on Readers' Service Card


Now it's even easier to hit your target,




Human Primary Passaged
Fibroblasts




Human Embryonic Kidney
Cell Line (293)




Rat Adrenal Pheochromocytoma
(PC12)




Baby Hamster Kidney
Cell Line (BHK-21)



Human Breast Carcinoma
(SK-BR-3)



African Green Monkey Fibroblasts
(COS-7)



Human Neuroblastoma
(BE(2)C)

with LIPOFECTAMINE PLUS Reagent.

Aim for better transfection with the newest addition to Life Technologies' broad spectrum of established, dependable GIBCO BRL™ products for transfection, an integral part of your state-of-the-art gene expression studies.

Enhance your protocols with our media, serum, selective antibiotics and lipid reagents, and further increase transfection of your cells, including those that are hard to transfect, with LIPOFECTAMINE PLUS™ Reagent.

LIPOFECTAMINE PLUS Reagent consists of LIPOFECTAMINE™ Reagent, the most efficient and popular cationic lipid reagent for transfecting DNA, and the proprietary PLUS Reagent for precomplexing the DNA. When used together, the LIPOFECTAMINE PLUS Reagent results in unparalleled performance in a wide variety of adherent eukaryotic cell types.

Cell lines successfully transfected
with LIPOFECTAMINE PLUS Reagent:

NIH 3T3	HT-29
MRC5	COS-7
HeLa S3	CHO-DXB11
SK-BR-3	BHK-21
Hep G2	MCDK
PC12	293
CHO-K1	HT1080
BE(2)C	Human Fibroblast

Highest Transfection Efficiencies

- Two to more than five times higher peak efficiencies than with other commercially available transfection reagents and methods.
- Advantageous for both transient and stable transfections.

Less Optimization Required

- Broad range of activity improves reproducibility and eliminates need for exhaustive optimization experiments, saving time and materials.

Less DNA Required

- Half as much precious DNA is needed per transfection as before, so you can actually do more experiments with less material.

Use With or Without Serum

- Outstanding performance in the presence or absence of serum, permitting use with cell types of differing sensitivity.

Product	Cat. No.	Size
LIPOFECTAMINE PLUS Reagent	10964-013	125 transfections

U.S. Academic and Government Orders/TECH-LINE™: (800) 828-6686

U.S. Industrial Orders/TECH-LINE: (800) 874-4226

Internet Ordering: www.lifetech.com



More Technical Information
www.lifetech.com

LIFE TECHNOLOGIES™

Producer of GIBCO BRL Products

U.S. Academic & Government Fax Orders: (800) 331-2286 U.S. Industrial Fax Orders: (800) 352-1468

Latin America Orders: To Order/TECH-LINE: (301) 840-4027 • Fax: (301) 258-8238

Canada Orders: To Order: (800) 263-6236 • TECH-LINE: (800) 757-8257 • Fax: (800) 387-1007

Circle No. 19 on Readers' Service Card

These products are for laboratory research use only and are not intended for any human or animal diagnostic, therapeutic, or other clinical uses, unless otherwise stated. ©1997 Life Technologies, Inc. 97-253



FONDATION ARES-SERONO
THE ARES-SERONO FOUNDATION

The Ares-Serono Foundation Fellowships in Biomedicine

1998 Award Announcement

FELLOWSHIPS IN REPRODUCTIVE ENDOCRINOLOGY

Two Fellowships will be awarded by The Ares-Serono Foundation for postdoctoral training pertaining to studies in the field of reproductive endocrinology, based on an international competition.

Fellowship Terms

- Full-time postdoctoral training
 - 2 years of support
 - USD 40,000 annual grant towards salary and expenses for postdoctoral training
-

Eligibility

- Applicants must have completed a PhD/MD or equivalent academic degree within 3 years from the start date of the fellowship
 - Ability to communicate fluently in English (verbal and written)
 - Preference will be given to candidates applying for a postdoctoral training in an Institute other than the one where their final academic degree was obtained.
-

Schedule

Application deadline: February 28th, 1998
Grants announced: July 15th, 1998
Fellowships start: October 1998

For the Application Form and Eligibility Guidelines, please contact:

Maria Grazia Calì
Secretary of the Board
Via Casilina 125
00176 Rome, Italy
FAX +39-6-70384577
Tel. +39-6-70384513/721
Internet address: <http://www.serono.ch>
E-mail address: ares-serono.foundation@pn.itnet.it



FONDATION ARES-SERONO
THE ARES-SERONO FOUNDATION

1998 Sponsored Scientific Workshops

VTH INTERNATIONAL WORKSHOP ON CYTOKINES

The Congress Center, Florence, Italy

March 16-18, 1998

Scientific Organizers

A.K. Abbas (USA)

Harvard Medical School, Boston, MA, USA

S. Romagnani

University of Florence Medical School, Florence, Italy

INTERNATIONAL WORKSHOP ON GROWTH, REPRODUCTIVE AND ENDOCRINE COMPLICATIONS IN THALASSAEMIA

The Congress Center, Ferrara, Italy

April 2-4, 1998

Scientific Organizers

V. De Sanctis (I)

Arcispedale Sant'Anna, Ferrara, Italy

R. Stanhope (UK)

University College of London Medical School, London, UK

B. Wonke (UK)

The Whittington Hospital, London, UK

11TH WORKSHOP ON DEVELOPMENTAL FUNCTION OF REPRODUCTIVE ORGANS GENETIC AND ENDOCRINE BASIS OF GONADAL FAILURE

Artis Zoo, Amsterdam, The Netherlands

April 16-18, 1998

Scientific Organizer

B.C.J.M. Fauser (NL)

University Hospital Rotterdam, Rotterdam, The Netherlands

CLINICAL APPLICATION OF DIFFERENTIATION THERAPY

Houston, TX, USA

October 1-3, 1998

Scientific Organizers

R. Lotan (USA)

University of Texas, Houston, TX, USA

S. Waxman (USA)

Mount Sinai Medical Center, New York, NY, USA

FOR FURTHER INFORMATION

Mailing Address:

The Ares-Serono Foundation, P.O. Box 7228, 00100 Rome (Nomentano) Italy

Tel.: +39-6-70384 513/721 - Fax: +39-6-70384 577

E-mail Address:

ares-serono.foundation@pn.itnet.it

Internet Address:

<http://www.serono.ch>

SEE THE FUTURE...

Science's Tech.Sight

NEW FROM SCIENCE!

Tech.Sight gives insight on leading-edge technology from the experts, including:

- ★ **Tech View:** Detailed technology reviews
- ★ **Tech Sightings:** Techniques summaries of new techniques and technologies
- ★ **Tech.Sight Online:** Full-text version of the print material and enhanced online features

SCIENCE
www.sciencemag.org


UPCOMING TOPICS

Tech.Sight publishes the 3rd Friday of each month. Upcoming topics include:

17 OCT: Structure-activity relationships by nuclear magnetic resonance—its impact and use, along with combinatorial chemistry and pharmacokinetics, on rational drug design
Space reservation deadline: 26 September

21 NOV: Single Cell Laser Microdissection
Space reservation deadline: 29 October

19 DEC: Animal Models for AIDS Research
Space reservation deadline: 26 November



The industry's leading surgical services team adds a full-time D.V.M. and M.D.

Unmatched commitment, doctoral level personnel and the ability to perform everything from routine hypophysectomies to complex cannulations and stereotaxic procedures (all performed under direct veterinary supervision) make Charles River the logical

CHARLES RIVER ANNOUNCES A NEW HEAD OF OPERATIONS

choice to meet your surgical services needs. Put Charles River's new head of operations in charge, call 1-800-LAB-RATS today.



Charles River
LABORATORIES


Contributing to the Search for Healthier Lives™

1-800-LAB-RATS • <http://www.criver.com>

© Charles River Laboratories, 1997

Circle No. 24 on Readers' Service Card

PROBING the
improbable



Analysis of W1282X mutation using a slab gel format.

PCR DNA samples (25 ng) of either wild-type homozygous (N/N) or carrier heterozygous (X/N) were denatured and hybridized with 0.5 pmol of fluorescein labeled wild-type PNA (WT), or mutant PNA (M). (Reprinted with permission from Proceedings of the National Academy of Science.)

Break the bounds of DNA. Peptide Nucleic Acid (PNA) probes empower your research with superior detection and binding capabilities. Exclusively from PerSeptive Biosystems.

Accelerate discovery with PNA PreGel Hybridization, a swift and precise alternative to Southern Blotting.

Higher affinity. A neutral peptide-like backbone ensures **faster** hybridization. Enhanced **specificity**. PNA probes allow for single base pair discrimination. Remarkable **clarity**. See what you have never seen before.

See PNA. Call PerSeptive Biosystems for a FREE applications overview on PNA probes.

Circle No. 45 on Readers' Service Card



www.pbio.com

US 1.800.899.5858 / Germany +49 6122 9830 0
France +33 134 5230 30 / UK +44 1992 5071 00
Japan +81 3 5570-9050



PerSeptive Biosystems

FAST FORWARD is a trademark of PerSeptive Biosystems, Inc.
©1997 PerSeptive Biosystems, Inc. All rights reserved. Printed in USA.